Attached files
| file | filename |
|---|---|
| EX-99.2 - INDOXIMOD PRESS RELEASE - LUMOS PHARMA, INC. | nlnk-20130603amxex992.htm |
| EX-99.3 - ALGENPANTUCEL PRESS RELEASE - LUMOS PHARMA, INC. | nlnk-20130603amxex993.htm |
| EX-99.1 - TERGENPUMATUCEL PRESS RELEASE - LUMOS PHARMA, INC. | nlnk-20130603amxex991.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 3, 2013 (June 1, 2013)
NewLink Genetics Corporation | ||
(Exact name of registrant as specified in its charter) | ||
Delaware | 001-35342 | 42-1491350 |
(State or other jurisdiction | (Commission | (IRS Employer |
of incorporation) | File Number) | Identification No.) |
2503 South Loop Drive Ames, IA | 50010 | |
(Address of principal executive offices) | (Zip Code) | |
Registrant's telephone number, including area code: (515) 296-5555 | ||
Not applicable | ||
(Former name or former address, if changed since last report.) | ||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Section 8 - Other Events
Item 8.01. Other Events.
On June 1, 2013, NewLink Genetics (NASDAQ:NLNK) announced results from a Phase 2 clinical study with tergenpumatucel-L.
The press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
On June 3, 2013, NewLink Genetics (NASDAQ:NLNK) announced results from two clinical studies with indoximod, an orally administered small molecule drug candidate that inhibits the IDO pathway.
The press release is attached hereto as Exhibit 99.2 and incorporated herein by reference.
On June 3, 2013, NewLink Genetics (NASDAQ:NLNK) also announced results from a Phase 2 clinical study with its drug candidate algenpantucel-L.
The press release is attached hereto as Exhibit 99.3 and incorporated herein by reference.
Section 9 - Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit Number | Description | |
99.1 | Press Release, dated June 1, 2013, entitled “NewLink Genetics Presents Positive Phase 2 Data on Novel Immunotherapy, Tergenpumatucel-L, in Non-Small Cell Lung Cancer at the ASCO 2013 Annual Meeting” | |
99.2 | Press Release, dated June 3, 2013, entitled “NewLink Genetics Presents Results from Two Phase 1 Studies with Immunotherapy Agent, Indoximod, at the ASCO 2013 Annual Meeting” | |
99.3 | Press Release, dated June 3, 2013, entitled “NewLink Genetics' Algenpantucel-L Shows Encouraging Disease-Free and Overall Survival in Phase 2 Study in Resected Pancreatic Cancer” | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: June 3, 2013
NewLink Genetics Corporation | |
By: | /s/ Gordon H. Link, Jr. |
Gordon H. Link, Jr. | |
Its: | Chief Financial Officer |
INDEX TO EXHIBITS
Exhibit Number | Description | |
99.1 | Press Release, dated June 1, 2013, entitled “NewLink Genetics Presents Positive Phase 2 Data on Novel Immunotherapy, Tergenpumatucel-L, in Non-Small Cell Lung Cancer at the ASCO 2013 Annual Meeting” | |
99.2 | Press Release, dated June 3, 2013, entitled “NewLink Genetics Presents Results from Two Phase 1 Studies with Immunotherapy Agent, Indoximod, at the ASCO 2013 Annual Meeting” | |
99.3 | Press Release, dated June 3, 2013, entitled “NewLink Genetics' Algenpantucel-L Shows Encouraging Disease-Free and Overall Survival in Phase 2 Study in Resected Pancreatic Cancer” | |